Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is an Open-label, Phase 1b/2 Study of the Pressure-Enabled Hepatic Artery Infusion (HAI)
of SD-101, a TLR9 agonist, Alone or in Combination with Intravenous Checkpoint Blockade in
Adults with Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC).